Komori
Treasury Shares4577Daito Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding the Status of Share Repurchases

In March 2026, the company purchased 208,800 of its own shares for approximately ¥305 million. Cumulative purchases based on the resolution of the Board of Directors totaled 883,200 shares, with a total purchase price of approximately ¥1,181 million.

Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
305442800
¥
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Market purchases on the Tokyo Stock Exchange

Resolved 10 October 2025 / Acquisition period 15 October 2025 to 22 May 2026 ※2 (based on contract date)

88.3%
Cumulative utilization rate
Limit
Number of Shares1,000,000 shares (maximum)
—
No Track Record Reported
Limit
Amount¥1.5 billion (maximum)

The darker band is the portion acquired this time (1 March 2026 to 31 March 2026 ※1 (based on settlement date)).

Number of Shares
Limit1,000,000 shares (maximum)
Cumulative total883,200 shares (as of 31 March 2026)
Current208,800 shares
Amount
Limit¥1.5 billion (maximum)
Cumulative total¥1,180,521,300 (as of 31 March 2026)
Current¥305,442,800
Percentage of total issued shares3.3%
Average acquisition price for this transaction (calculated)¥1,463 per shareCurrent acquisition price ÷ current number of shares acquired

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction208,800 shares
Total current acquisition price¥305,442,800
Acquisition date/acquisition period1 March 2026 to 31 March 2026 ※1 (based on settlement date)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Cumulative number of shares acquired883,200 shares (as of 31 March 2026)
Cumulative acquisition cost¥1,180,521,300 (as of 31 March 2026)
Resolution date10 October 2025
Maximum number of shares to be acquired1,000,000 shares (maximum)
Total acquisition price¥1.5 billion (maximum)
Acquisition period under the resolution15 October 2025 to 22 May 2026 ※2 (based on contract date)
Percentage of total issued shares3.3%
Items this document does not state (2)
Whether acquisition has been completedAverage Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The disclosure states that the purchases were carried out, but does not state the reason for the purchases.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Repurchases | Daito Pharmaceutical Co.,Ltd. (4577) timely disclosure | Komori